The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Open accessAbstract
BACKGROUND: Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. METHODS: We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). The primary end point was a composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke. The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. Follow-up lasted 18 to 36 months (mean, 24). RESULTS: The median LDL cholesterol level achieved during treatment was 95 mg per deciliter (2.46 mmol per liter) in the standard-dose pravastatin group and 62 mg per deciliter (1.60 mmol per liter) in the high-dose atorvastatin group (P<0.001). Kaplan-Meier estimates of the rates of the primary end point at two years were 26.3 percent in the pravastatin group and 22.4 percent in the atorvastatin group, reflecting a 16 percent reduction in the hazard ratio in favor of atorvastatin (P=0.005; 95 percent confidence interval, 5 to 26 percent). The study did not meet the prespecified criterion for equivalence but did identify the superiority of the more intensive regimen. CONCLUSIONS: Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen. These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, in the PROVE-IT TIMI 22 trial, intensive lipid-lowering with atorvastatin 80 mg reduced LDL-C by 51% and triglycerides by 20%, compared with 22% and 11% reductions with pravastatin (40 mg/day) and was associated with greater protection against death or major cardiovascular events [72].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [72]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Likewise, in the PROVE-IT TIMI 22 trial, intensive lipid-lowering with atorvastatin 80 mg reduced LDL-C by 51% and triglycerides by 20%, compared with 22% and 11% reductions with pravastatin (40 mg/day) and was associated with greater protection against death or major cardiovascular events [72].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [72]
In the citing paper
“Lipid profile has long been considered among the most important risk factors for CVD in T2DM, and several trials have confirmed that lowering low-density lipoprotein cholesterol (LDL-C) via statins in T2DM was effective in reducing the risk of CVD [81, 82].”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [81]
In the citing paper
“In addition to their initial events, such patients are at substantial risk for recurrent, potentially fatal events.”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [7]
In the citing paper
“Because cardiovascular event rates are increased in people with diabetes and established ASCVD, intensive therapy is indicated and has been shown to be of bene fi t in multiple large meta-analyses and randomized cardiovascular outcomes trials (91,99,105,107,108).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [107]
In the citing paper
“These recommendations are based on the observation that high-intensity versus moderate-intensity statin therapy reduces cardiovascular event rates in high-risk individuals with established cardiovascular disease in randomized trials (95,107).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [107]
In the citing paper
“In the PACIFIC study740), which was a multicenter observational registry study on ACS, the incidence rate of fatal and nonfatal myocardial infarction was high, at 35/1,000 person-years, despite approximatively 80% subjects being administered statins.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [740]
In the citing paper
“The results of these studies have found that, compared to patients with normal renal function, the risk for cardiovascular events, including cerebrovascular disease, cardiac death, and total mortality increases by 2–3-fold in those with CKD even when the CKD is mild.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [740]
In the citing paper
“Recent clinical trials in high-risk patients, such as those with acute coronary syndromes or previous cardiovascular events (200–202), have demonstrated that more aggressive therapy with high doses of statins to achieve an LDL cholesterol of <70 mg/dl led to a significant reduction in further events.”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [200]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Self-citation(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D. J., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,475
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Research works printed but not linked: 1
- 1994, Lancet, 344, 1383
Cited by
Sorted by citations
Items 201–300 of 1,027
Weng, T.-C., Yang, Y.-H. K., Lin, S.-J., & Tai, S.-H. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01085.x · Cited by 345
Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome
Nicholls, S. J., Kastelein, J. J. P., Schwartz, G. G., Bash, D., Rosenson, R. S., Cavender, M. A., Brennan, D. M., Köenig, W., Jukema, J. W., Nambi, V., et al. (2014) · JAMA · doi:10.1001/jama.2013.282836 · Cited by 345
Beyond Low-Density Lipoprotein Cholesterol
Arsenault, B. J., Rana, J. S., Stroes, E. S. G., Després, J.-P., Shah, P. K., Kastelein, J. J. P., Wareham, N. J., Boekholdt, S. M., & Khaw, K.-T. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.057 · Cited by 342
Bohula, E. A., Giugliano, R. P., Cannon, C. P., Zhou, J., Murphy, S. A., White, J. A., Tershakovec, A. M., Blazing, M. A., & Braunwald, E. (2015) · Circulation · doi:10.1161/circulationaha.115.018381 · Cited by 340
Self-citationWiviott, S. D., Cannon, C. P., Morrow, D. A., Ray, K. K., Pfeffer, M. A., & Braunwald, E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.064 · Cited by 340
Self-citationAcute Coronary Syndromes: Diagnosis and Management, Part II
Kumar, A., & Cannon, C. P. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60674-5 · Cited by 340
Self-citation(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30156-5 · Cited by 338
2014 ESC/EACTS Guidelines on myocardial revascularization
Windecker, S., Kolh, P. H., Alfonso, F., Collet, J., Cremer, J., Falk, V., Filippatos, G. S., Hamm, C. W., Head, S. J., Jüni, P., et al. (2015) · EuroIntervention · doi:10.4244/eijy14m09_01 · Cited by 339
Grundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 334
Sachdeva, A., Cannon, C. P., DEEDWANIA, P. C., LaBresh, K. A., Smith, S. C., Dai, D., Hernandez, A. F., & Fonarow, G. C. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.08.010 · Cited by 331
Self-citation8. Cardiovascular Disease and Risk Management
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s011 · Cited by 329
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 345
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation
Hoogeveen, R. C., & Ballantyne, C. M. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa252 · Cited by 322
Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates
Lentine, K. L., Costa, S. P., Weir, M. R., Robb, J. F., Fleisher, L. A., Kasiske, B. L., Carithers, R. L., Ragosta, M., Bolton, K., Auerbach, A. D., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823eb07a · Cited by 322
Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus
Navarese, E. P., Buffon, A., Andreotti, F., Koziński, M., Welton, N. J., Fabiszak, T., Caputo, S., Grześk, G., Kubica, A., Świątkiewicz, I., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.037 · Cited by 315
Anti-inflammatory therapeutics for the treatment of atherosclerosis
Charo, I. F., & Taub, R. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3444 · Cited by 314
Link, B. G., & Phelan, J. C. (2012) · Handbooks of sociology and social research · doi:10.1007/978-94-007-4276-5_25 · Cited by 314
Ezetimibe therapy: mechanism of action and clinical update
Toth, P. P., Phan, B. A. P., & Dayspring, T. D. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33664 · Cited by 312
Liao, J. K. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.009 · Cited by 310
High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial
PAIVA, H., THELEN, K., COSTER, R., SMET, J., PAEPE, B., MATTILA, K., LAAKSO, J., LEHTIMAKI, T., VONBERGMANN, K., & LUTJOHANN, D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.03.006 · Cited by 308
Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management
Chehade, J. M., Gladysz, M., & Mooradian, A. D. (2013) · Drugs · doi:10.1007/s40265-013-0023-5 · Cited by 308
Wadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.11.010 · Cited by 306
McPherson, R., Frohlich, J. J., Fodor, G. J., & Genest, J. J. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70310-5 · Cited by 306
Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Zhou, Q., & Liao, J. K. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315684 · Cited by 301
Gislason, G., Rasmussen, J. N., Abildstrom, S. Z., Gadsbøll, N., Buch, P., Friberg, J., Rasmussen, S., Køber, L., Stender, S., Madsen, M., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi705 · Cited by 304
Taylor, A. J., Lee, H. J., & Sullenberger, L. E. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x148508 · Cited by 303
Cellular and Mitochondrial Effects of Alcohol Consumption
Manzo‐Ávalos, S., & Saavedra‐Molina, A. (2010) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph7124281 · Cited by 303
Slager, C., Wentzel, J. J., Gijsen, F. J. H., Thury, A. Á., van der Wal, A. C., Schaar, J., & Serruys, P. W. J. C. (2005) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0298 · Cited by 301
Ridker, P. M., & Torres, J. (2006) · JAMA · doi:10.1001/jama.295.19.2270 · Cited by 300
Reith, C. A., Baigent, C., Blackwell, L. S., Emberson, J., Spata, E., Davies, K., Halls, H. J., Holland, L., Wilson, K., Armitage, J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01545-8 · Cited by 301
Self-citationPathophysiology and treatment of atherosclerosis
Bergheanu, S. C., Bodde, M. C., & Jukema, J. W. (2017) · Netherlands Heart Journal · doi:10.1007/s12471-017-0959-2 · Cited by 299
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., Leon, J. D., Glass, A. D., & Reiss, A. B. (2021) · Metabolites · doi:10.3390/metabo11100690 · Cited by 299
Chapman, M. J., Le Goff, W., Guerin, M., & Kontush, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp399 · Cited by 298
McKinney, J. S., & Kostis, W. J. (2012) · Stroke · doi:10.1161/strokeaha.112.655894 · Cited by 294
Arbab‐Zadeh, A., Nakano, M., Virmani, R., & Fuster, V. (2012) · Circulation · doi:10.1161/circulationaha.111.047431 · Cited by 292
Koren, M. J., & Hunninghake, D. B. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.053 · Cited by 292
Antibiotic Treatment ofChlamydia pneumoniaeafter Acute Coronary Syndrome
Cannon, C. P., Braunwald, E., McCabe, C. H., Grayston, J. T., Muhlestein, B., Giugliano, R. P., Cairns, R., & Skene, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043528 · Cited by 291
Self-citationAnderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.028 · Cited by 282
Ray, K. K., & Cannon, C. P. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.086 · Cited by 276
Self-citationShepherd, J., Kastelein, J. J. P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., & Wenger, N. K. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04371206 · Cited by 275
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
Institute of Medicine (2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 274
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828478ac · Cited by 275
C‐Reactive Protein (CRP)‐Lowering Agents
Prasad, K. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2006.00033.x · Cited by 274
Schwartz, G. G., Abt, M., Bao, W., DeMicco, D., Kallend, D., Miller, M., Mundl, H., & Olsson, A. G. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.544 · Cited by 272
Aggressive Versus Moderate Lipid-Lowering Therapy in Hypercholesterolemic Postmenopausal Women
Raggi, P., Davidson, M. H., Callister, T. Q., Welty, F. K., Bachmann, G. A., Hecht, H. S., & Rumberger, J. A. (2005) · Circulation · doi:10.1161/circulationaha.104.512681 · Cited by 272
Stone, N. J., Bilek, S., & Rosenbaum, S. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.006 · Cited by 272
Charytan, D., & Kuntz, R. E. (2006) · Kidney International · doi:10.1038/sj.ki.5001934 · Cited by 271
2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction
Russian Society of Cardiology (2020) · Russian Journal of Cardiology · doi:10.15829/29/1560-4071-2020-4103 · Cited by 271
Disorders of lipid metabolism. Clinical Guidelines 2023
Владиславович, Е. М., Kukharchuk, V. V., Сергиенко, И. В., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Dm, A., Arutyunov, G. P., Ахмеджанов, Н. М., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 270
Diamantis, E., Kyriakos, G., Quiles-Sánchez, L. V., Farmaki, P., & Troupis, T. G. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x13666170426104611 · Cited by 267
KONES, R. J. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 266
The Evolving Future of PCSK9 Inhibitors
Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264
Self-citationHydrophilic or Lipophilic Statins?
Climent, E., Benaiges, D., & Pedro‐Botet, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.687585 · Cited by 264
de Groot, E., van Leuven, S. I., Duivenvoorden, R., Meuwese, M. C., Akdim, F., Bots, M. L., & Kastelein, J. J. P. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1163 · Cited by 263
Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
Effects of Icosapent Ethyl on Total Ischemic Events
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.032 · Cited by 259
Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease
Arya, S., Khakharia, A., Binney, Z. O., DeMartino, R. R., Brewster, L. P., Goodney, P. P., & Wilson, P. W. F. (2018) · Circulation · doi:10.1161/circulationaha.117.032361 · Cited by 257
Corti, R., Worthley, S. G., Helft, G., Viles-Gonzalez, J. F., Badimon, J. J., Corti, R., Fuster, V., Fayad, Z. A., Worthley, S. G., Helft, G., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.03.054 · Cited by 257
Koskinas, K. C., Siontis, G. C. M., Piccolo, R., Mavridis, D., Räber, L., Mach, F., & Windecker, S. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx566 · Cited by 257
Chapman, M. J., Assmann, G., Fruchart, J., Shepherd, J., & Sirtori, C. R. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004402 · Cited by 257
Binder, C. J., Shaw, P. X., Chang, M.-K., Boullier, A., Hartvigsen, K., Hörkkö, S., Miller, Y. I., Woelkers, D., Corr, M., & Witztum, J. L. (2005) · Journal of Lipid Research · doi:10.1194/jlr.r500005-jlr200 · Cited by 254
Schmermund, A., Achenbach, S. S., Budde, T., Buziashvili, Y. I., Förster, A., Friedrich, G. J., Henein, M., Kerkhoff, G., Knollmann, F. D., Kukharchuk, V. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.568147 · Cited by 254
Global Perspective on Acute Coronary Syndrome
Vedanthan, R., Seligman, B. J., & Fuster, V. (2014) · Circulation Research · doi:10.1161/circresaha.114.302782 · Cited by 253
Tardif, J.-C., Ballantyne, C. M., Barter, P., Dasseux, J.-L., Fayad, Z. A., Guertin, M.-C., Kastelein, J. J. P., Keyserling, C., Klepp, H., Koenig, W., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu171 · Cited by 251
Self-citation2011 ACCF/AHA guideline for coronary artery bypass graft surgery: Executive summary
Hillis, L. D., Smith, P. K., Anderson, J. L., Bittl, J. A., Bridges, C. R., Byrne, J. G., Cigarroa, J. E., DiSesa, V. J., Hiratzka, L. F., Hutter, A. M., et al. (2011) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2011.10.015 · Cited by 251
Nicholls, S. J., Brandrup‐Wognsen, G., Palmer, M. K., & Barter, P. J. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.08.651 · Cited by 251
Cannon, C. P., de Lemos, J. A., Rosenson, R. S., Ballantyne, C. M., Liu, Y., Gao, Q., Palagashvili, T., Alam, S., Mues, K. E., Bhatt, D. L., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.1810 · Cited by 250
Self-citationVitamin Intervention for Stroke Prevention Trial
Spence, J. D., Bang, H., Chambless, L. E., & Stampfer, M. J. (2005) · Stroke · doi:10.1161/01.str.0000185929.38534.f3 · Cited by 248
Abrams, J. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042317 · Cited by 246
Taguchi, I., Iimuro, S., Iwata, H., Takashima, H., Abe, M., Amiya, E., Ogawa, T., Ozaki, Y., Sakuma, I., Nakagawa, Y., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032615 · Cited by 244
Alsheikh-Ali, A. A. A., Maddukuri, P. V., Han, H., & Karas, R. H. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.073 · Cited by 243
Guidelines for the treatment and management of new‐onset diabetes after transplantation1
Wilkinson, A. H., Davidson, J. A., Dotta, F., Home, P., Keown, P. A., KIBERD, B. A., Jardine, A. G., Levitt, N. S., Marchetti, P., MARKELL, M. S., et al. (2005) · Clinical Transplantation · doi:10.1111/j.1399-0012.2005.00359.x · Cited by 242
Pinkosky, S. L., Filippov, S. I., Srivastava, R. A. K., Hanselman, J. C., Bradshaw, C. D., Hurley, T. R., Cramer, C. T., Spahr, M. A., Brant, A. F., Houghton, J. L., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m030528 · Cited by 241
Wilson, P. W. F., Polonsky, T. S., Miedema, M. D., Khera, A., Kosinski, A. S., & Kuvin, J. T. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.004 · Cited by 239
Pijlman, A. H., Huijgen, R., Verhagen, S. N., Imholz, B. P. M., Liem, A. H., Kastelein, J. J. P., Abbink, E. J., Stalenhoef, A. F. H., & Visseren, F. L. J. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.09.014 · Cited by 238
Lupus Atherosclerosis Prevention Study (LAPS)
Petri, M. A., Kiani, A. N., Post, W. S., Christopher‐Stine, L., & Magder, L. S. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.136762 · Cited by 240
Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes
Howard, B. V. (2008) · JAMA · doi:10.1001/jama.299.14.1678 · Cited by 238
8. Cardiovascular Disease and Risk Management
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s011 · Cited by 239
Deedwania, P., Stone, P. H., Bairey Merz, C. N., Cosin-Aguilar, J., Koylan, N., Luo, D., Ouyang, P., Piotrowicz, R., Schenck-Gustafsson, K., Sellier, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.654756 · Cited by 236
Clinical Perspectives of Statin-Induced Rhabdomyolysis
Antons, K., Williams, C. D., Baker, S. K., & Phillips, P. S. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.007 · Cited by 236
Ballantyne, C. M., Abate, N. I., Yuan, Ž., King, T. R., & Palmisano, J. J. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.11.023 · Cited by 236
Ridker, P. M., Morrow, D. A., Rose, L. M., Rifai, N., Cannon, C. P., & Braunwald, E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.080 · Cited by 236
Self-citationThum, T., Tsikas, D., Stein, S., Schultheiß, M., Eigenthaler, M., Anker, S. D., Poole-Wilson, P. A., Ertl, G., & Bauersachs, J. K. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.066 · Cited by 234
Lipid lowering with PCSK9 inhibitors
Dadu, R. T., & Ballantyne, C. M. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.84 · Cited by 234
Lincoff, A. M., Tardif, J., Schwartz, G. G., Nicholls, S. J., Rydén, L., Neal, B. C., Malmberg, K., Wedel, H., Buse, J. B., Henry, R. R., et al. (2014) · JAMA · doi:10.1001/jama.2014.3321 · Cited by 232
2023 Chinese guideline for lipid management
Li, J., Zhao, S., Zhao, D. H., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190934 · Cited by 241
High-Density Lipoprotein and Coronary Heart Disease
Natarajan, P., Ray, K. K., & Cannon, C. P. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.008 · Cited by 231
Self-citationGoff, D. C., Gerstein, H. C., Ginsberg, H. N., Cushman, W. C., Margolis, K. L., Byington, R. P., Buse, J. B., Genuth, S., Probstfield, J. L., & Simons-Morton, D. G. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.002 · Cited by 229
Imaging of coronary atherosclerosis: intravascular ultrasound
Garcia-Garcia, H. M., Costa, M. A., & Serruys, P. W. J. C. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq280 · Cited by 228
O’Donoghue, M. L., Morrow, D. A., Sabatine, M. S., Murphy, S. A., McCabe, C. H., Cannon, C. P., & Braunwald, E. (2006) · Circulation · doi:10.1161/circulationaha.105.612630 · Cited by 228
Self-citationNiacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?
Bangalore, S., Qin, J., Sloan, S., Murphy, S. A., Cannon, C. P., & for the PROVE IT-TIMI 22 Trial Investigators (2010) · Circulation · doi:10.1161/circulationaha.109.905687 · Cited by 227
Self-citationTsimikas, S., Witztum, J. L., Miller, E. R., Sasiela, W. J., Szarek, M., Olsson, A. G., & Schwartz, G. G. (2004) · Circulation · doi:10.1161/01.cir.0000141728.23033.b5 · Cited by 225
Evidence for Statin Pleiotropy in Humans
Liu, P., Liu, Y.-W., Lin, L.-J., Chen, J.-H., & Liao, J. K. (2008) · Circulation · doi:10.1161/circulationaha.108.813311 · Cited by 224
9. Cardiovascular Disease and Risk Management
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s012 · Cited by 223
Cyclophilin A Is Secreted by a Vesicular Pathway in Vascular Smooth Muscle Cells
Suzuki, J., Jin, Z., Meoli, D. F., Matoba, T., & Berk, B. C. (2006) · Circulation Research · doi:10.1161/01.res.0000216405.85080.a6 · Cited by 221
2018 Guidelines for the management of dyslipidemia
Rhee, E., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, B. J., Choi, S., et al. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.188 · Cited by 221
Vaughan, C. J., & Gotto, A. M. (2004) · Circulation · doi:10.1161/01.cir.0000139312.10076.ba · Cited by 220
Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease
O’Donoghue, M. L., Morrow, D. A., Tsimikas, S., Sloan, S., Ren, A. F., Hoffman, E. B., Desai, N. R., Solomon, S. D., DOMANSKI, M. J., Arai, K., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.042 · Cited by 223
Self-citation
Metadata
- Authors
- Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Pennsylvania (US)
- Université de Montréal (CA)
- Bristol-Myers Squibb (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-08
- Volume
- 350
- Issue
- 15
- Pages
- 1495-1504
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159449551
- Cited by
- 4,938
- References
- 32
- Citations by year
- 2026: 87 · 2025: 84 · 2024: 121 · 2023: 117 · 2022: 120 · 2021: 129 · 2020: 147 · 2019: 163 · 2018: 155 · 2017: 215 · 2016: 178 · 2015: 216 · 2014: 213 · 2013: 215 · 2012: 229
- FWCI
- 442.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- acute coronary syndrome, statins, intensive lipid-lowering therapy, LDL cholesterol, pravastatin, atorvastatin, non-inferiority, major adverse cardiovascular events, revascularization, myocardial infarction, stroke, unstable angina
- MeSH terms
- Atorvastatin, Angina, Unstable, Anticholesteremic Agents, Cardiovascular Diseases, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Proportional Hazards Models, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
